EVT0185 | ATP citrate lyase inhibitor

CAS:
 2588489-03-4
Catalog Number:
 10-4113

Available Options

Size:PriceQuantity 
5 mg$125.00
25 mg$425.00
Request Quote / Bulk / Custom Size
Product Inquiry

EVT0185 (2588489-03-4) is an orally bioavailable ACLY (ATP citrate lyase) inhibitor (IC50 = 460 nM). It is converted to its active CoA thioester form in hepatocytes.  Unlike bempedoic acid, EVT0185 inhibits AMPKß and also inhibits ACC1, ACC2, and ACSS2. It reduced tumor burden and synergized with lenvatinib, anti-PDL1, and VEGFR antibodies in multiple MASH-hepatocellular carcinoma mouse models. EVT0185 enhanced tumor immunogenicity via promotion of tumor-infiltrating B cells.

References/Citations:

  1. Gautam et al. (2025), ACLY inhibition promotes tumour immunity and suppresses liver cancer; Nature, 645 507
2588489-03-4, ACLY inhibitor, EVT-0185, EVT0185, EVT0185 supplier
CAS:
2588489-03-4
Catalog Number:
10-4113
Activity:
ATP citrate lyase inhibitor
Chemical Names:
6-[4-(5-Carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid
Molecular Weight:
362.51
Molecular Formula:

C22H34O4

Solubility:
Soluble in DMSO (>25 mg/ml)
Physical Properties:
White solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

EVT0185 (2588489-03-4) is an orally bioavailable ACLY (ATP citrate lyase) inhibitor (IC50 = 460 nM). It is converted to its active CoA thioester form in hepatocytes.  Unlike bempedoic acid, EVT0185 inhibits AMPKß and also inhibits ACC1, ACC2, and ACSS2. It reduced tumor burden and synergized with lenvatinib, anti-PDL1, and VEGFR antibodies in multiple MASH-hepatocellular carcinoma mouse models. EVT0185 enhanced tumor immunogenicity via promotion of tumor-infiltrating B cells.

References/Citations:

  1. Gautam et al. (2025), ACLY inhibition promotes tumour immunity and suppresses liver cancer; Nature, 645 507

STEM CELL

BOGO